Virbac SA - Company Profile
Powered by 
All the sales intelligence you need on Virbac SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Virbac SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Virbac SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Virbac SA (Virbac) is a veterinary healthcare company. The company develops and distributes pharmaceuticals, vaccines, and diagnostic tools for domestic animals and livestock. Its products include vaccines, antibiotics, parasiticides, dental products, nutrition, diagnosis, anti-inflammatory drugs, and dermatological products. Virbac’s products also include ear cleanser for dogs and cats; food supplement for cattle; tablets for the prevention of canine heartworm disease and treatment of roundworms and hookworms; and general anesthetics, among others. The company's products are utilized by veterinarians, farmers, and pet owners. It operates manufacturing, research, and development, and subsidiaries in Europe, North America, Latin America, Asia-Pacific, Africa, and the Middle East. Virbac is headquartered in Carros, Provence-Alpes-Cote d'Azur, France.
Headquarters
France
Address
13e Rue Lid - Bp 27, Carros, Provence - Alpes- Cote d'Azur, 06511
Website
corporate.virbac.com
Telephone
33 492 087100
No of Employees
6,442
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VIRP (EPA)
Revenue (2025)
$1.7B
4.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
3.9%
(2025 vs 2024)
Market Cap*
$3.7B
Net Profit Margin (2025)
XYZ
-1.0%
(2025 vs 2024)
* As of and is in US$
Virbac SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Vaccines | CaniLeish |
| Antibiotics | Veterinary HPM |
| Parasiticides | Cydectin Platinum |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Purchase | In December, the company acquired Thyronorm from Norbrook Laboratories Limited for GBP100 million. |
| 2025 | Contracts/Agreements | In September, the company renewed its agreement with Kyndryl to continue managing its IBM i servers and build a new private cloud environment. |
| 2025 | New Products/Services | In July, the company introduced two complementary oral vaccines specifically designed to prevent post-weaning diarrhea (PWD) and edema disease (ED) in piglets caused by F4 and F18 factors. |
Competitor Comparison
| Key Parameters | Virbac SA | Elanco Animal Health Inc | Idexx Laboratories Inc | Ceva Sante Animale SA | Vetoquinol SA |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | France | France |
| City | Carros | Greenfield | Westbrook | Libourne | Lure |
| State/Province | Provence - Alpes- Cote d'Azur | Indiana | Maine | Aquitaine | Haute Normandie |
| No. of Employees | 6,442 | 9,000 | 11,000 | 7,000 | 2,500 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marie-Helene Dick-Madelpuech | Chairwoman | Executive Board | 2020 | 60 |
| Paul Martingell | Chief Executive Officer | Senior Management | 2025 | - |
| Pierre Madelpuech | Vice Chairman | Executive Board | 1995 | 64 |
| Bertrand Havrileck | Head - Corporate R&D | Senior Management | 2021 | 63 |
| Francesca Cortella | Head - Corporate Human Resources | Senior Management | 2015 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer